Have Your Say: Review the First UK SACT Protocol and Provide Feedback
Dear Colleagues working in cancer services
We are writing to invite you to review and provide feedback on the first protocol produced as part of the UK SACT Protocols Pilot.
The pilot, delivered through a partnership between the UK SACT Board and Pharmaceutical Press, is exploring the feasibility of developing standardised SACT protocols for use across the United Kingdom. The aim is to improve consistency, support safe and evidence-based practice, reduce duplication of effort, and establish robust governance and content standards for future protocol development.
Currently, there is no single source of SACT protocols across the UK, resulting in variation in protocol content, governance, and implementation between organisations. Through this pilot, we are testing whether a UK-wide approach can provide a more consistent, efficient, and clinically robust model for protocol development and maintenance.
As this work is being developed for the benefit of cancer services across all four nations, feedback from those involved in the prescribing, verification, preparation, administration, governance, and delivery of SACT is essential.
Have Your Say
This is the first protocol produced through the UK SACT Protocols Pilot, and we want to ensure it is clinically robust, practical, and usable across cancer services throughout the UK.
Please take 10-15 minutes to review the protocol and complete the feedback questionnaire by scanning the QR code below. Your feedback will directly influence revisions to this protocol and help shape the content, structure, and governance of future UK SACT Protocols currently in development.
Scan the QR code below to access the protocol and feedback form: https://www.pharmaceuticalpress.com/usage/sact-protocolamivantamab-sc-with-lazertinib/

We would particularly welcome your views on:
-The overall scope and structure of the protocol
-Clinical content and completeness
-Usability within local cancer services
-Suitability for implementation within local governance frameworks
-Areas where greater clarity or standardisation may be required
-Any content that you feel should be added, amended, or removed
-Any other comments or suggestions
The feedback form will remain open; however, we would encourage feedback to be submitted as soon as possible. Early feedback will allow us to refine both this protocol and the additional protocols that are currently being developed as part of the pilot.
Important information
Please note: This protocol is being shared as part of a pilot feedback exercise only. It is not for clinical use and must not be used to support patient care, prescribing decisions, protocol approval processes, or local clinical practice.
The content remains the intellectual property of Pharmaceutical Press. We ask that recipients do not copy, redistribute, republish, adapt, incorporate into local documentation, or otherwise use the content beyond the purposes of this review and feedback exercise.
We would be grateful if you could also share this invitation with relevant colleagues within your organisation, including pharmacists, oncologists, nurses, and other members of the multidisciplinary team who use or rely upon SACT protocols in practice.
Thank you for taking the time to support this important UK-wide initiative. Your feedback will help determine whether a UK-wide protocol model is feasible and will shape the future development of UK SACT Protocols.
Kind regards,
Alex
Alex McPhail, Content Manager (New Products)
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, UK
Working Days: Monday-Thursday